Real-World Patient Characteristics, Treatment Patterns, and Treatment Outcomes of Patients With Diffuse Large B-Cell Lymphoma by Line of Therapy
Source : https://pubmed.ncbi.nlm.nih.gov/38597118/
In this real-world analysis, 25.2% of patients experienced R/R-DLBCL after 1L with poor outcomes. Given the findings of this study, there is a high unmet need for novel, safe, and...
One- and 3-year real-world OS rates from first-line initiation were 88.5% and 78.4%, respectively. Patients who received later lines of therapy experienced numerically lower 1- and 3-year real-world OS.
Prediction of Immunochemotherapy Response for Diffuse Large B-Cell Lymphoma Using Artificial Intelligence Digital Pathology
Source : https://pubmed.ncbi.nlm.nih.gov/38584594/
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and prevalent subtype of aggressive non-Hodgkin lymphoma that poses diagnostic and prognostic challenges, particularly in predicting drug responsiveness. In this study, we...
The multimodal prediction model achieved an impressive area under the ROC curve of 0.856, demonstrating significant associations with clinical variables such as Ann Arbor stage, International Prognostic Index, and bulky disease.
Impact of Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation in Non-Hodgkin Lymphoma
Source : https://pubmed.ncbi.nlm.nih.gov/38607394/
Prior studies have demonstrated that certain populations including older patients, racial/ethnic minority groups, and women are underrepresented in clinical trials. We performed a retrospective analysis of patients with Non-Hodgkin Lymphoma...
Lower participation rates were associated with lower neighborhood socioeconomic status, including higher poverty rates and living in crowded households. Racial composition of census tract was not associated with differences in trial participation.
Post-Infusion PD-1+CD8+CAR-T Cells Identify Patients Responsive to CD19-CAR-T Therapy in Non-Hodgkin's Lymphoma
Source : https://pubmed.ncbi.nlm.nih.gov/38607381/
Chimeric antigen receptor T cell therapy (CAR-T) has revolutionized treatment for relapsed/refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL). Robust biomarkers and a complete understanding of CAR-T cell function in the post-infusion...
Researchers found that the presence of postinfusion PD-1–positive, CD8-positive CAR T cells at the day 14 timepoint highly correlated with the ability to achieve complete response by 6 months.
Antigen-Independent, Autonomous B Cell Receptor Signaling Drives Activated B Cell DLBCL
This study describes and characterizes antigen-independent, autonomous signaling of the clonal B cell receptor as an intrinsic oncogenic driver in activate
Autonomous BCR signaling was associated with IgM isotype, dependent on somatic BCR mutations and individual HCDR3 sequences, and largely restricted to non-GCB DLBCL.